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Abstract
Introduction—Vitamin D (VD) is part of a complex steroid hormone system long known to be
involved in bone metabolism. Recently, VD has been implicated physiologic processes as diverse
as vascular health, immune function, metabolism and placental function. This review summarizes
the current evidence for the role of VD in perinatal health.
Methods—A systematic review of articles published in PubMed between May 2010 and October
2011 was undertaken using key words for VD and pregnancy. Seventy-eight studies were
reviewed.
Findings—The biologic evidence regarding a role for VD in reproductive outcomes is strong,
and rates of VD deficiency may be high among pregnant women. However, no consensus exists
regarding optimum VD levels in pregnancy or standard measurement of VD deficiency. Clinical
studies establishing an association between VD levels and adverse pregnancy outcomes such as
preeclampsia, gestational diabetes, low birthweight, preterm labor, cesarean delivery and
infectious diseases have conflicting results. This is likely due to a paucity of randomized trials,
heterogeneity of populations studied, and low sample size with poor adjustment for confounding
among observational studies.
Conclusion—Further research should focus on defining optimum 25(OH)D levels in pregnancy
as well as among various subgroups of the population. Randomized trials are needed to determine
if VD supplementation can improve pregnancy outcomes. Currently, ACOG and IOM recommend
600 IU of daily VD supplementation during pregnancy to support maternal and fetal bone
metabolism.
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Introduction
Vitamin D (VD) deficiency in the form of rickets was first described in the 17th century. [1]
The “vitamin”—actually a fat-soluble steroid hormone—was not discovered until the early
20th century. A successful public health campaign, centered on cod liver oil supplementation
and fortification of dairy products, was thought to have reduced VD deficiency in developed
countries. [2] Recently, the prevalence of rickets has increased sparking a new interest in
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VD deficiency. In addition, studies of VD physiology suggest that effects of VD deficiency
could be much broader than rickets including cardiovascular disease, cancers, diabetes, and
pregnancy complications.
The naturally occurring form of VD in humans is cholecalciferol or Vitamin D3. [3, 4] It can
be ingested in the diet (animal products) or produced in the skin when UV light interacts
with a cholesterol derivative. Vitamin D2 or ergocalciferol is derived from plant sterols and
is the form contained in most VD supplements. Both D2 and D3 travel in the blood bound to
VD Binding Protein and must be hydroxylated to become active. D3 and D2 metabolites are
thought to have equal physiologic activity but D3 levels may increase more quickly after
supplementation. Current assays may perform differently when measuring D2 or D3
metabolites.
25(OH)D is first hydroxylated in the liver. The resulting metabolite, 25(OH)D, is very stable
and is therefore most commonly used to measure VD status. The second hydroxylation to
the active form 1,25(OH)D occurs mostly in the kidneys in a process tightly regulated by
calcium, phosphorus and parathyroid hormone levels. [5] After the second hydroxylation,
1,25(OH)D binds to the VD Receptor (VDR). VDR is a transcription factor whose products
are involved in a wide array of activities including bone metabolism, cellular growth and
differentiation, glucose metabolism and immune function. Both the enzyme responsible for
VD activation (1αhydroxyase) and its receptor have been located in peripheral tissues such
as the placenta suggesting a farther-reaching role for VD than bone metabolism alone. (See
Figure 1). [6]
During pregnancy, serum levels of 1,25(OH)D increase up to 2-fold starting at 10-12 weeks
of gestation and reaching a maximum in the third trimester. [4] It is unclear whether
25(OH)D levels increase during pregnancy. [7] However, given an increase in the active
form of VD, pregnant women likely have a higher cellular exposure to VD during the
second and third trimesters suggesting a role for VD in obstetric well being. Perinatal
outcomes hypothesized to be related to VD include preeclampsia, gestational diabetes, low
birth weight, preterm delivery, cesarean section, and infectious disease. This review will
summarize scientific literature published in the last 18 months regarding the potential role of
VD in improving perinatal outcomes.
Methods
Medline was searched with key words related to VD and pregnancy. We limited the search
to English language articles published between May 1, 2010 and October 31, 2011.
Inclusion criteria were human or animal pregnant subjects, perinatal outcomes, and in vitro,
animal, case control, cohort, systematic review or clinical trial study design. Articles
reporting on infant, childhood, or long-term maternal outcomes associated with maternal VD
status were excluded.
The Medline search resulted in 250 citations. After abstract review, 137 were excluded due
to lack of pregnant subjects, perinatal outcomes, or original research. After full text review,
38 additional articles were excluded that were not original research. The remaining 75
articles were reviewed. The reference sections of the articles were hand searched for
additional citations; three such studies were reviewed. Key articles published prior to May
2010 were reviewed in order to provide context.
Vitamin D physiology in pregnancy
VDR and 1αhydroxylase are active in reproductive tissues, but their roles in those tissues
are still being elucidated. In pregnant mice, VDR was expressed differentially throughout
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pregnancy in placental, decidual, and ovarian follicular tissue supporting the hypothesis that
VD is integrally involved in the physiologic changes of pregnancy. [8] Enquobahrie et. al.
compared gene expression profiles of pregnant women with low levels of VD (<25.5ng/ml)
to those with higher levels (>31.7ng/ml). Over 300 genes showed significant differences in
expression of at least 1.5 fold. [9] Affected genes were known to be involved in a variety of
functions such as angiogenesis, carbohydrate metabolism, and immune function.
One mechanism whereby VD may affect pregnancy outcomes is modulation of the immune
response. 1,25(OH)D and 25(OH)D treatments of human trophoblast cells significantly
altered the innate immune response. [10, 11] In VDR or 1αhydroxylase knockout mice,
trophoblast cells had an increased inflammatory response to bacterial components compared
with wild type cells. [12] Treatment of wild type cells with 25(OH)D significantly
suppressed the inflammatory response compared to that of untreated cells. In human
syncytiotrophoblastic cells, high doses of VD decreased markers of oxidative stress. [13]
Identifying Vitamin D Deficiency
Measuring VD deficiency in pregnant women is complicated by a lack of agreement among
researchers in three areas: whether 25(OH)D levels are the most accurate markers of
deficiency, what level of 25(OH)D should be considered optimal in pregnant women, and
which test of VD deficiency is the most accurate.
25(OH)D is the clinical and research gold standard measure of VD status. However, given
the complexity of the VD system, it is unclear whether 25(OH)D levels have the same
clinical implications in all women or throughout all stages of pregnancy. For example,
although 25(OH)D levels were lower among black women than Caucasian women in one
study, their VD Binding Protein levels were also lower resulting in equivalent levels of
calculated free 1,25(OH)D. [14] Some researchers suggest measuring Parathyroid Hormone
levels as a biologic marker of VD deficiency. However, Parathyroid Hormone levels have
been inconsistently associated with 25(OH)D levels pregnant women. [15-19] This may be
due to a threshold effect: Parathyroid Hormone levels are only increased when 25(OH)D is
very low (e.g. 20ng/L). However, such a threshold has not been identified. [19]
According to the 2010 Institute of Medicine (IOM) Report, 12ng/L (30nmol/L) of 25(OH)D
is the point below which “persons are at risk for bone deficiency”. “Some but not all are
potentially at risk” with levels below 20ng/L (50nmol/L). [20] However, the 2011 ACOG
Practice Bulletin “Vitamin D: Screening and Supplementation” defines deficiency as
25(OH)D levels less than 20ng/L (50nmol/L). [21] These cut points and others are used to
define VD deficiency in different studies; therefore levels of “VD deficiency” in various
populations cannot be directly compared.
Finally, there are multiple commercially available 25(OH)D assays, which do not yield
identical results. This makes comparing data from multiple studies more complicated. [22,
23] Historically 25(OH)D has been measured with protein binding immunoassays, but liquid
chromatography with tandem mass spectroscopy may be the most accurate technology. [24]
Vitamin D deficiency and risk factors in pregnancy
Using the IOM cut points, 7% of U.S. pregnant or lactating women in a large national
database were at risk for VD deficiency (<12ng/L) and an additional 21% were at risk for
inadequacy in 2006 (<20ng/L). [25] These levels have not changed since 2001. Using the
20ng/L cut point, however, studies from around the world show high percentages of VD
deficiency during pregnancy: 100% of Somali immigrants in Sweden, 98% of Omani
women, 96% of urban Indian women, 89% of urban Japanese women, 69% of urban
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Chinese women, 54.7% of UK women in the first trimester, 50% of Baltimore teens, 46% of
laboring women from Pakistan, 41% of South Carolina women, 41% of U.S. women in a
national database, 35-46% of Australian women, 24% of Western Canadian women, and 7%
of North Carolina women. [7, 15, 16, 22, 26-37]
Non-modifiable risk factors consistently associated with deficiency are winter season and
darker skin pigmentation. Modifiable risk factors include less sun exposure (geography or
clothing-related), less dietary intake of foods high in VD or VD supplements, and higher
BMI. Unfortunately, not all studies control for the same risk factors or measure risk factors
in a standard way, therefore it is difficult to compare results directly between populations.
Treating Vitamin D deficiency in pregnancy
Sun exposure is measured by a variety of methods: latitude, season, skin coverage with
clothing, skin pigmentation, and ethnicity. However, in all studies, more sun exposure is
significantly associated with increased VD levels. Sun exposure may be more strongly
associated with VD levels than oral VD intake. [22] There are no trials of sun exposure to
increase VD levels in pregnancy.
VD supplementation likely increases 25(OH)D levels. Supplemented women had less VD
deficiency in 3 large well-controlled cohorts (N=1539), a similar trend in one poorer quality
study (N=201) and no difference in one study with an overall low rate of supplementation
(N=559). [7, 16, 22, 27, 28] RCTs of VD supplementation have consistently shown success
in raising 25(OH)D levels in pregnant women and neonates albeit with varying doses of
25(OH)D. [38] Only one negative trial is reported in the literature, and the dose was 400IU.
All other doses were higher, ranging from 800-1000 IU/day to 100,000-200,000 IU given as
one-time doses. Despite increases with supplementation, 25(OH)D levels remained low in
most studies. A recent randomized, double-blinded placebo controlled trial occurred in
pregnant South Carolina women. The treatment arms were 2000 IU VD daily plus standard
prenatal vitamins and 4000 IU VD daily plus standard prenatal vitamins compared with a
placebo arm consisting of a placebo pill plus standard prenatal vitamins. The mean VD level
measured at 36 weeks was 79 nmol/L for the control group, 105 for the 2000 IU group, and
119 for the 4000 IU group. This difference was statistically significant (p<0.0001); however,
the levels were higher than most other trials even in the placebo group. Unfortunately,
almost 30% of the participants were excluded from the analysis based on “poor adherence”.
Although the intervention decreased “VD deficiency”, no difference was found in perinatal
outcomes measured. In its 2011 report, the IOM recommended 600 IU per day of 25(OH)D
for pregnant women specifically to support bone metabolism and no more than 4000 IU per
day to avoid hypercalcemia. [20] ACOG endorses these recommendations and proposes
1000-2000 IU per day of 25(OH)D when deficiency is identified (<20ng/ml). [21]
Dietary intake may be another avenue to increase VD levels. VD deficiency is not as high as
expected in countries at higher latitudes (less sun exposure) such as northern Europe, the
U.S. and Canada. [39] This finding may be explained by the higher rates of cod liver oil
supplementation and fortified dairy products in these countries. Women with a diet higher in
dairy, poultry and eggs had less VD deficiency in Pakistan. [26] U.S. women with lower VD
dietary intake had more deficiency. [17, 27, 28] All data regarding diet are self-reported.
There are no clinical trials regarding increasing VD status through dietary modification.
Vitamin D and pregnancy outcomes
A 2010 systematic review of first trimester 25(OH)D levels and adverse pregnancy
outcomes concluded that evidence regarding the association between VD levels and
pregnancy complications such as preeclampsia and diabetes is inconclusive but warrants
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further investigation. [40] The five studies reviewed were nested case control studies and
only a minority controlled for dietary quality or intake of VD. This is perplexing and could
result in confounding; dietary quality is likely associated with adverse pregnancy outcomes
as well as VD deficiency. Recent observational studies investigating the associations
between 25(OH)D levels in pregnant women and perinatal outcomes are summarized below.
The only recent randomized trial of VD supplementation found no change in birthweight,
gestational age at delivery or cesarean delivery among supplemented women despite
increased circulating levels of 25(OH)D.
Gestational Hypertension/Preeclampsia
VD and its receptor are active in the human placenta and immune modulation suggesting a
causative role for VD deficiency and preeclampsia. This hypothesis has been supported by a
cohort study of women exposed and unexposed to VD supplementation, one RCT of VD
supplements, and one RCT of fish oil supplements. [41-43] Women exposed to VD
developed less preeclampsia. A 2011 systematic review found that hypertension in
pregnancy is more common in winter or rainy seasons when VD deficiency is also higher.
[44] Higher VD levels have been consistently associated with lower preeclampsia incidence
and lower blood pressure when measured at diagnosis or delivery. [45-47] However, it is
unclear which comes first. Therefore, several groups have sought to determine wither
25(OH)D levels measured prior to the diagnosis of preeclampsia are associated with the
diagnosis. [14, 48-51] [52] The findings of these mostly case control studies are mixed. The
two cohort studies found no association. There are likely several reasons this inconsistency:
1) small sample sizes leading to insufficient power, 2) different control groups (some studies
excluded “complicated pregnancies”), 3) racial/ethnic and socioeconomic heterogeneity of
populations studied, 4) different methods of measuring 25(OH)D concentration, 5) different
cut points for VD deficiency, and 6) incomplete adjustment for confounding by VD dietary
intake and sun exposure. Overall, the findings suggest that 25(OH)D levels in early
pregnancy may be associated with later preeclampsia only in specific subgroups: women
with very low levels of 25(OH)D (<13.2 ng/L) or African American women.
Gestational Diabetes
In non-pregnant adults, VD deficiency has been associated with higher levels of Type 2
Diabetes. Studies investigating the relationship between VD levels and gestational diabetes
(GDM) have mixed results. Three recent case control studies from India, the UK and North
Carolina aimed to determine whether early pregnancy 25(OH)D levels were associated with
a later diagnosis of GDM. [53-55] Results were mixed. In one, women with GDM had 2.7
times the odds (CI 1.0-7.0) of VD deficiency in the first trimester as those without. A second
showed no association between low VD levels and a GDM diagnosis but did find increased
fasting glucose and hemoglobin a1c at 28 weeks. The third found no association between
diagnosis of GDM and first trimester VD deficiency but had very wide confidence intervals.
None of the studies were adjusted for dietary factors or sun exposure.
Birth Weight
Vitamin D is known to be involved in bone metabolism, therefore VD deficiency has been
hypothesized to be associated with low birth weight. Study results have been mixed both for
the association between low birthweight and VD status at delivery and between low birth
weight and first trimester 25(OH)D levels. [28, 56-59] The largest cohort study (3730
Amsterdam women) found the odds of birthing a baby small for gestational age was higher
among women with severe VD deficiency in early pregnancy (<12ng/L). [60] No studies
fully controlled for sun exposure or dietary factors. Taken together, these data suggest that if
an association between VD status and infant birth weight exists, it may vary according to
subgroups such as severe VD deficiency or race. A potential mechanism for the latter was
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suggested by Swamy et. al. [61] In a study of VDR haplotypes among a cohort of 615
pregnant women, 8 polymorphisms in black women were significantly associated with
infant birthweight, and no polymorphisms in white women were associated with
birthweight.
Preterm Delivery
Given the known association between VD deficiency and increased markers of
inflammation, some have suggested a role for VD in prevention of preterm birth. Only a
handful of studies have investigated this question. In a recent North Carolina study, 40 cases
who suffered a preterm birth without evidence of chorioamnionitis were matched by age and
race with three controls. [36] No association between first trimester 25(OH)D deficiency
(<50nmol/L) and spontaneous preterm birth was found. The power was low given low
incidence of preterm birth and VD deficiency in this upper class population. A Japanese
retrospective study found lower mean 25(OH)D among women in the 3rd trimester that had
been hospitalized for preterm labor earlier in the pregnancy but delivered at term compared
with those who had not been. [37]
Cesarean delivery
Severe VD deficiency and rickets causes pelvic deformities, which have been known for
many years to increase the risk of obstructed labor. In 2009, a Boston study of 300 women
found women with VD levels <37.5ng/L had four times the odds of a cesarean delivery than
those with higher levels. [62] A Northern California study found no change in mean VD
levels between women who underwent cesarean delivery and those who did not after
adjustment for confounders. [28] Neither study was adjusted for dietary factors although the
California study adjusted for sun exposure. The RCT of VD supplementation in South
Carolina, found no difference in Cesarean section rates between treatment and control
groups. [18]
Infectious Diseases
VD is involved in immune function. Several groups have investigated associations between
VD levels and infectious diseases during pregnancy. In a North Carolina case control study
(Cases=117 Controls=118), women less than 26 weeks of gestation with periodontal disease
had 2 times the odds of VD deficiency. In a US national cohort study (N=3523), there was
no association between Bacterial Vaginosis and VD status in non-pregnant women;
however, in pregnant women, VD deficiency (<30ng/L) was independently associated with
Bacterial Vaginosis (OR 2.9, CI 1.1-7.3). [63] HIV mortality, disease progression and
anemia were associated with VD deficiency (<32ng/L) in a cohort of HIV positive
Tanzanian pregnant women. [64] None of the studies adjusted for dietary factors or sun
exposure.
Conclusion
Biologic data suggests a role for VD in women’s reproductive health. However, results from
studies investigating the link between 25(OH)D levels and adverse pregnancy outcomes are
contradictory. This is likely due to small sample sizes, inadequate control for confounding,
significant heterogeneity in populations studied, and significant heterogeneity in exposure
measurement. [41] A standard definition of VD deficiency in pregnancy must be
determined. A pooled analysis of observational studies could then be considered. VD is
likely involved in reproductive health; however, it is unlikely to be the cure for pregnancy
complications that have multifactorial etiologies. Until we have clear evidence for optimal
levels during pregnancy, IOM guidelines recommending 600IU of daily VD
supplementation for pregnant women should be followed.
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1. Vitamin D is involved in reproductive health.
2. Optimal Vitamin D levels in pregnancy are unknown.
3. No conclusive evidence links lower levels of 25(OH)D with adverse pregnancy
outcomes.
4. Pregnant women should receive 600IU of Vitamin D supplementation daily.
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Vitamin D metabolism and tissue actions. 25(OH)D, 25-hydroxy vitamin D; Ca2+, calcium;
CRP, C-reactive protein; DBP, vitamin D binding protein; DM, diabetes mellitus; MMP9,
matrix metalloproteinase 9; PO4, phosphate; PTH, parathyroid hormone; SGA, small for
gestational age; UVB, ultraviolet B.
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